Nephros 510(k) woes
This article was originally published in The Gray Sheet
Kidney dialysis product maker plans to meet with FDA to discuss next steps after the agency rejected a 510(k) pre-market submission for the firm's hemodiafiltration (HDF) system, designed to improve quality of life in end-stage renal disease (ESRD) patients. FDA sent a not-substantially-equivalent decision letter to the firm June 30, but Nephros says it had no opportunity to address the agency's questions before the decision was rendered. "We feel that the issues raised in the current letter are addressable," the company said July 7. According to the firm, the HDF system removes harmful substances from patients' blood "more effectively, and with greater capacity, than existing ESRD treatment methods." After meeting with FDA, Nephros plans to file a new 510(k) or appeal the current decision
You may also be interested in...
Joint Commission urges caution in imaging
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker